Development of vaccines against the sexually transmitted infections gonorrhoea, syphilis, Chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus

The success in preventing hepatitis B virus and human papillomavirus infections by means of vaccination paves the way for the development of other vaccines to prevent sexually transmitted infections (STIs) such as gonorrhoea, syphilis, chlamydia, herpes simplex virus, human immunodeficiency virus an...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Vaccines and Immunotherapy 2020, Vol.8
Main Author: McIntosh, Edwin David G.
Format: Article
Language:English
Subjects:
Chlamydia
Gonorrhea
Hepatitis B
Herpes simplex
Herpes viruses
HIV
Human immunodeficiency virus
Human papillomavirus
Immunization
Infections
Latency
Neonates
Review
Sexually transmitted diseases
STD
Syphilis
Vaccine development
Vaccines
Zika virus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The success in preventing hepatitis B virus and human papillomavirus infections by means of vaccination paves the way for the development of other vaccines to prevent sexually transmitted infections (STIs) such as gonorrhoea, syphilis, chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus. The current status of vaccine development for these infections will be explored in this review. The general principles for success include the need for prevention of latency, persistence and repeat infections. A reduction in transmission of STIs would reduce the global burden of disease. Therapeutic activity of vaccines against STIs would be advantageous over preventative activity alone, and prevention of congenital and neonatal infections would be an added benefit. There would be an added value in the prevention of long-term consequences of STIs. It may be possible to re-purpose ‘old’ vaccines for new indications. One of the major challenges is the determination of the target populations for STI vaccination.
ISSN:2515-1355
2515-1363
DOI:10.1177/2515135520923887